NO20081924L - 7-[2-[4-(6-fluor-3-metyl-1,2-benzisoksazol-5-yl)-1-pipera-zinyl]etyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5-amin - Google Patents

7-[2-[4-(6-fluor-3-metyl-1,2-benzisoksazol-5-yl)-1-pipera-zinyl]etyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5-amin

Info

Publication number
NO20081924L
NO20081924L NO20081924A NO20081924A NO20081924L NO 20081924 L NO20081924 L NO 20081924L NO 20081924 A NO20081924 A NO 20081924A NO 20081924 A NO20081924 A NO 20081924A NO 20081924 L NO20081924 L NO 20081924L
Authority
NO
Norway
Prior art keywords
zinyl
benzisoxazol
triazolo
pyrazolo
propynyl
Prior art date
Application number
NO20081924A
Other languages
English (en)
Other versions
NO341760B1 (no
Inventor
Samuel Chackalamannil
Craig D Boyle
Unmesh G Shah
Jean E Lachowicz
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37487759&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081924(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20081924L publication Critical patent/NO20081924L/no
Publication of NO341760B1 publication Critical patent/NO341760B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Forbindelsen med strukturformel I, eller et farmasøytisk akseptabelt salt derav, er beskrevet, så vel som dens anvendelse ved behandling av sentralnervesystemsykdommer, i særdeleshet Parkinsons sykdom, ekstrapyramidalt syndrom, urolig leggsyndrom og oppmerksomhetssvekket hyperaktivitetsforstyrrelse, farmasøytiske preparater omfattende den, og kombinasjoner med andre midler. (I)
NO20081924A 2005-09-23 2008-04-22 7-[2-[4-(6-fluor-3-metyl-1,2-benzisoksazol-5-yl)-1-piperazinyl]etyl]-2-(1-propynyl)-7Hpyrazolo-[ 4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5-amin, eller et farmasøytisk akseptabelt salt derav, farmasøytiske preparater derav, samt dets anvendelse ved behandling av sentralnervesystemsykdommer. NO341760B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72002705P 2005-09-23 2005-09-23
PCT/US2006/037003 WO2007038284A1 (en) 2005-09-23 2006-09-21 7-[2-[4-(6-FLUORO-3-METHYL-1,2-BENZISOXAZOL-5-YL)-1-PIPERAZINYL]ETHYL]-2-(1-PROPYNYL)-7H-PYRAZOLO-[4,3-e]-[1,2,4]-TRIAZOLO-[1,5-c]-PYRIMIDIN-5 AMINE

Publications (2)

Publication Number Publication Date
NO20081924L true NO20081924L (no) 2008-05-22
NO341760B1 NO341760B1 (no) 2018-01-15

Family

ID=37487759

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081924A NO341760B1 (no) 2005-09-23 2008-04-22 7-[2-[4-(6-fluor-3-metyl-1,2-benzisoksazol-5-yl)-1-piperazinyl]etyl]-2-(1-propynyl)-7Hpyrazolo-[ 4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5-amin, eller et farmasøytisk akseptabelt salt derav, farmasøytiske preparater derav, samt dets anvendelse ved behandling av sentralnervesystemsykdommer.

Country Status (31)

Country Link
US (2) US7572802B2 (no)
EP (1) EP1937687B1 (no)
JP (1) JP4808779B2 (no)
KR (1) KR101396614B1 (no)
CN (2) CN101273045B (no)
AR (1) AR056080A1 (no)
AT (1) ATE503759T1 (no)
AU (1) AU2006294633B8 (no)
BR (1) BRPI0616264B8 (no)
CA (1) CA2623047C (no)
CY (1) CY1111921T1 (no)
DE (1) DE602006021042D1 (no)
DK (1) DK1937687T3 (no)
EC (1) ECSP088297A (no)
ES (1) ES2361856T3 (no)
HK (1) HK1119681A1 (no)
HR (1) HRP20110466T1 (no)
IL (1) IL190275A (no)
MY (1) MY146429A (no)
NO (1) NO341760B1 (no)
NZ (1) NZ566737A (no)
PE (1) PE20070521A1 (no)
PL (1) PL1937687T3 (no)
PT (1) PT1937687E (no)
RS (1) RS51702B (no)
RU (1) RU2417997C2 (no)
SG (1) SG165419A1 (no)
SI (1) SI1937687T1 (no)
TW (1) TWI335329B (no)
WO (1) WO2007038284A1 (no)
ZA (1) ZA200802550B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ527142A (en) 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US7723343B2 (en) * 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
CN102438624B (zh) 2009-03-13 2016-03-30 阿德维纳斯治疗私人有限公司 取代的稠合嘧啶化合物
EP2462144B1 (en) 2009-08-07 2017-09-20 Merck Sharp & Dohme Corp. PROCESS FOR PREPARING A 2-ALKYNYL SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
CA2812378C (en) * 2010-09-24 2016-11-29 Advinus Therapeutics Limited Fused tricyclic compounds as adenosine receptor antagonist
WO2012135083A1 (en) * 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. METABOLITES OF 7-(2-(4-(6-FLUORO-3-METHYLBENZO[d]ISOXAZOL-5-YL)PIPERAZIN-1-YL)ETHYL)-2-(PROP-1-YNYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2014101113A1 (en) * 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
JPWO2014128882A1 (ja) * 2013-02-21 2017-02-02 医療法人 和楽会 不安うつ病の治療薬
WO2015027431A1 (en) 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
JP6701214B2 (ja) * 2014-11-03 2020-05-27 イオメット ファーマ リミテッド 医薬化合物
US10085991B2 (en) 2014-12-04 2018-10-02 Merck Sharp & Dohme Corp. Formulation inhibiting effects of low acid environment
CN106543095B (zh) * 2016-09-23 2019-03-05 江苏大学 一种基于2-羟基苯乙酮肟及其衍生物一锅制备苯并异噁唑的方法
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists
CN110742893B (zh) * 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE462170B (sv) 1987-10-27 1990-05-14 Aahlstrom Corp Avlaegsnande av loesta och kolloidala makromolekylaera organiska aemnen ur effluenter
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
US5565460A (en) 1993-07-27 1996-10-15 Kyowa Hakko Koygo Co., Ltd. Therapeutic purine agents for parkinson's disease
IT1275420B (it) 1995-06-02 1997-08-05 Schering Plough S P A Metodo per misurare l'affinita' di legame al recettore a2a dell'adenosina di componenti di interesse farmacologico mediante l'uso del ligando triziato (3h)-sch 58261
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
CN100384847C (zh) 2000-05-26 2008-04-30 先灵公司 腺苷A2a受体拮抗剂
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
CA2463598C (en) 2001-10-15 2009-09-08 Schering Corporation Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pyrimidines as adenosine a2a receptor antagonists
ES2354875T3 (es) 2002-12-19 2011-03-18 Schering Corporation Uso de antagonistas del receptor a2a de la adenosina para el tratamiento o prevención del síndrome extrapiramidal.
ES2326270T3 (es) * 2003-04-23 2009-10-06 Schering Corporation Antagonistas del receptor de la adenosina a2a 2-alquinil- y 2-alquenil-pirazolo-(4,3-e)-1,2,4-triazolo-(1,5-c)-pirimidina.
AU2005236059B2 (en) 2004-04-21 2009-01-15 Schering Corporation Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Also Published As

Publication number Publication date
RU2417997C2 (ru) 2011-05-10
CA2623047C (en) 2013-04-23
PT1937687E (pt) 2011-06-01
BRPI0616264B8 (pt) 2021-05-25
EP1937687B1 (en) 2011-03-30
HK1119681A1 (en) 2009-03-13
CN102716131B (zh) 2014-04-23
ZA200802550B (en) 2009-06-24
RS51702B (en) 2011-10-31
KR20080047423A (ko) 2008-05-28
HRP20110466T1 (hr) 2011-08-31
TWI335329B (en) 2011-01-01
NO341760B1 (no) 2018-01-15
SI1937687T1 (sl) 2011-07-29
CN101273045A (zh) 2008-09-24
DK1937687T3 (da) 2011-07-18
CA2623047A1 (en) 2007-04-05
BRPI0616264A2 (pt) 2011-06-14
MY146429A (en) 2012-08-15
RU2008115239A (ru) 2009-10-27
PE20070521A1 (es) 2007-07-13
JP2009509959A (ja) 2009-03-12
ECSP088297A (es) 2008-04-28
SG165419A1 (en) 2010-10-28
CN101273045B (zh) 2012-02-01
ES2361856T3 (es) 2011-06-22
NZ566737A (en) 2011-09-30
AU2006294633A8 (en) 2012-03-29
DE602006021042D1 (de) 2011-05-12
EP1937687A1 (en) 2008-07-02
JP4808779B2 (ja) 2011-11-02
BRPI0616264B1 (pt) 2020-12-22
CY1111921T1 (el) 2015-11-04
AR056080A1 (es) 2007-09-19
WO2007038284A1 (en) 2007-04-05
TW200730531A (en) 2007-08-16
AU2006294633A1 (en) 2007-04-05
AU2006294633B8 (en) 2012-03-29
CN102716131A (zh) 2012-10-10
IL190275A (en) 2014-06-30
US20070072867A1 (en) 2007-03-29
PL1937687T3 (pl) 2011-09-30
US7572802B2 (en) 2009-08-11
AU2006294633B2 (en) 2012-03-01
ATE503759T1 (de) 2011-04-15
US8389532B2 (en) 2013-03-05
KR101396614B1 (ko) 2014-05-16
US20090270432A1 (en) 2009-10-29
IL190275A0 (en) 2009-09-22

Similar Documents

Publication Publication Date Title
NO20081924L (no) 7-[2-[4-(6-fluor-3-metyl-1,2-benzisoksazol-5-yl)-1-pipera-zinyl]etyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5-amin
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
SE0402735D0 (sv) Novel compounds
NO20084997L (no) Pyrazolo[3,4-D]pyrimidinderivater nyttige for a behandle andedrettssykdommer
EA201001017A1 (ru) 3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы
NO20075641L (no) Kroman og kromenderivater og ders anvendelse
NO20071915L (no) Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
ATE540948T1 (de) Pyrrolopyridine als proteinkinasehemmer
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
DK1812440T3 (da) Pyrazolo[1,5-a]pyrimidiner, der kan anvendes som inhibistorer af proteinkinaser
PE20121352A1 (es) Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3
TNSN06411A1 (en) Pyrimidine urea derivatives as kinase inhibitors
NO20083501L (no) Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
TW200734327A (en) Aminopyrimidines useful as kinase inhibitors
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
GT200600105A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos.
NO20082496L (no) Pyrazinderivater
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
PE20110584A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIMIDINA COMO INHIBIDORES DE MET, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU PROCEDIMIENTO DE PREPARACION
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP, US

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY

MM1K Lapsed by not paying the annual fees